Novel viral vaccine for treating non-small cell lung cancer and preparation method thereof

Abstract

The invention provides a novel viral vaccine for treating a non-small cell lung cancer and a preparation method thereof. The preparation method of the viral vaccine comprises the first step of constructing a carrier of an MVA virus and the second step of obtaining specificity presenting MAGE-3 antigen DC cells. According to the viral vaccine prepared through the method, the biological stability is high, adverse effects on human bodies are not produced, and pathogenic dangers do not exist; a virus antibody can obtain a large number of viral particles with high purity easily; MAGE-A3 expressed by the viral vaccine has better immunogenicity, more epitopes are achieved, and drug resistance is not prone to being caused; the viral load needed in inoculation of the viral vaccine is smaller than other viruses.

Description

technical field [0001] The invention belongs to the fields of biotechnology and oncology diagnosis, and in particular relates to a novel virus vaccine for treating non-small cell lung cancer and a preparation method thereof. Background technique [0002] Public statistics show that the incidence and mortality of lung cancer rank first among all malignant tumors in the world, and there are as many as 1,200,000 newly diagnosed cases worldwide every year. According to the statistics of the Ministry of Health (1992-1997), the mortality rate of male lung cancer accounted for 38% of all malignant tumors in big cities, and that of females accounted for 16%, both ranking first, accounting for about 25% of all tumors; about 40% of deaths due to lung cancer / 100,000, accounting for about 38% of all tumor deaths; the number of lung cancer deaths in my country reaches 500,000 people every year. In the past 30 years, the incidence and mortality of lung cancer in my country have been incr...

AI Technical Summary

Problems solved by technology

[0011] 1) Constructed with lentiviral vectors, disadvantages: poor biological safety, the virus may recover infectivity, the vector capacity is small, and cannot express large fragments of proteins. After loading large fragments of genes, the virus titer will be seriously reduced, and the infection efficiency of the virus will be further affected

[0012] 2) Use MAGEA3 antigen peptide plus adjuvant to assist in the generation of immune response. Disadvantages: The epitopes of antigen peptides are limited and cannot cover all immune sites. The spatial structure of artificially synthesized antigen peptides may be different from that of naturally occurring antigens, which hinders the production Normal immune response, with potential for side effects

[0013] 3) Other treatment methods: Construct PD-1 RNAi expression plasmid to inhibit PD-1 expression, the disadvantage is that it is easy to produce drug resistance

Images